169 related articles for article (PubMed ID: 35099990)
1. Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China : A Cohort Study.
Kang M; Yi Y; Li Y; Sun L; Deng A; Hu T; Zhang J; Liu J; Cheng M; Xie S; Luo M; Jiang J; Jiang Y; Tang S; He J
Ann Intern Med; 2022 Apr; 175(4):533-540. PubMed ID: 35099990
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
Ma C; Sun W; Tang T; Jia M; Liu Y; Wan Y; Han J; Rodewald L; Li J; Song Y; Wang Y; Wu D; Wang F; Zheng H; Tang L; Gao GF; Yin Z; An Z
Vaccine; 2022 May; 40(20):2869-2874. PubMed ID: 35400561
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.
He X; Zeng B; Wang Y; Pang Y; Zhang M; Hu T; Liang Y; Kang M; Tang S
Front Immunol; 2023; 14():1257360. PubMed ID: 37915583
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant-infected patients in Jiangsu, China.
Hu Z; Tao B; Li Z; Song Y; Yi C; Li J; Zhu M; Yi Y; Huang P; Wang J
Int J Infect Dis; 2022 Mar; 116():204-209. PubMed ID: 35065255
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.
Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS
Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case-control study.
Zhang X; Wang Y; Hu C; Xu P; Ma L; Liu L; Sun J; Liu Y; Yang H; Pan F; Hu J; Cao C; Cheng K; Gao D; Lyu Y; Qin W
Hum Vaccin Immunother; 2023 Dec; 19(1):2194189. PubMed ID: 36998173
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death.
Huang Z; Xu S; Liu J; Wu L; Qiu J; Wang N; Ren J; Li Z; Guo X; Tao F; Chen J; Lu D; Sun X; Wang W
BMC Med; 2022 Oct; 20(1):400. PubMed ID: 36266697
[TBL] [Abstract][Full Text] [Related]
8. Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study.
Tang L; Zhang Y; Wang F; Wu D; Qian ZH; Zhang R; Wang AB; Huang C; Wang H; Ye Y; Lu M; Wang C; Ma YT; Pan J; Li YF; Lv XY; An Z; Rodewald L; Wang XY; Shao YM; Wu ZY; Yin Z
BMJ Open; 2022 Nov; 12(11):e063919. PubMed ID: 36368753
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence - China, 2021.
Wu D; Zhang Y; Tang L; Wang F; Ye Y; Ma C; Zheng H; Yu W; Cao L; Song Y; Reyimu A; Zhang X; Wang H; Nie Y; Lu M; Qi M; Li J; Wang R; Yang K; Wang C; Rodewald LE; Gao GF; An Z; Yin Z
China CDC Wkly; 2022 Jan; 4(4):57-65. PubMed ID: 35186369
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of Inactivated COVID-19 Vaccines against Delta-Variant COVID-19: Evidence from an Outbreak in Inner Mongolia Autonomous Region, China.
Ma C; Huang C; Wang W; Song Y; Jiang X; Tian X; Liu B; Chi F; Lang S; Liu D; Sun W; Tang L; Wu D; Song Y; Li J; Rodewald L; Yin Z; An Z
Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851170
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India.
Malhotra S; Mani K; Lodha R; Bakhshi S; Mathur VP; Gupta P; Kedia S; Sankar J; Kumar P; Kumar A; Ahuja V; Sinha S; Guleria R; ; Dua A; Ahmad S; Sathiyamoorthy R; Sharma A; Sakya T; Gaur V; Chaudhary S; Sharma S; Madan D; Gupta A; Virmani S; Gupta A; Yadav N; Sachdeva S; Sharma S; Singh S; Pandey A; Singh M; Jhurani D; Sarkar S; Lokade AK; Mohammad A; Pandit S; Dubey R; Singh AK; Gohar N; Soni D; Bhattacharyya A; Rai S; Tummala S; Gupta I; Shukla S
JAMA Netw Open; 2022 Jan; 5(1):e2142210. PubMed ID: 34994793
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 infections among healthcare personnel in Pakistan: a test-negative case-control study.
Khan UI; Niaz M; Azam I; Hasan Z; Hassan I; Mahmood SF; Ali A
BMJ Open; 2023 Jun; 13(6):e071789. PubMed ID: 37369396
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness of booster vaccination of inactivated COVID-19 vaccines against susceptibility, infectiousness, and transmission of omicron BA.2 variant: a retrospective cohort study in Shenzhen, China.
Liao Y; Su J; Zhao J; Qin Z; Zhang Z; Gao W; Wan J; Liao Y; Zou X; He X
Front Immunol; 2024; 15():1359380. PubMed ID: 38881892
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China.
Xu H; Li H; You H; Zhang P; Li N; Jiang N; Cao Y; Qin L; Qin G; Qu H; Wang H; Zou B; He X; Li D; Zhao H; Huang G; Li Y; Zhang H; Zhu L; Qiao H; Li H; Liu S; Gu L; Yin G; Hu Y; Xu S; Guo W; Wang N; Liu C; Gao P; Cao J; Zheng Y; Zhang K; Wang Y; Chen H; Zhang J; Mu D; Niu J
Emerg Microbes Infect; 2023 Dec; 12(1):2149935. PubMed ID: 36398721
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 during Delta variant surge: a preliminary assessment from a case-control study in St. Petersburg, Russia.
Barchuk A; Bulina A; Cherkashin M; Berezina N; Rakova T; Kuplevatskaya D; Stanevich O; Skougarevskiy D; Okhotin A
BMC Public Health; 2022 Sep; 22(1):1803. PubMed ID: 36138385
[TBL] [Abstract][Full Text] [Related]
18. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study.
Huang Z; Xu S; Liu J; Wu L; Qiu J; Wang N; Ren J; Li Z; Guo X; Tao F; Chen J; Lu D; Wang Y; Li J; Sun X; Wang W
Nat Commun; 2023 Apr; 14(1):2009. PubMed ID: 37037803
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness of the inactivated COVID-19 vaccines against variant of concerns: meta-analysis.
Sarwar MU; Waasia FZ; Aloqbi AA; Alandiyjany M; Alqahtani RM; Hafiz LA; Shamlan G; Albreiki M
J Infect Public Health; 2024 Feb; 17(2):245-253. PubMed ID: 38141544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
